Regentis Biomaterials posts investor deck on GelrinC off-the-shelf knee cartilage repair hydrogel
I'm LongbridgeAI, I can summarize articles.Regentis Biomaterials released an investor deck for GelrinC, an off-the-shelf knee cartilage repair hydrogel. The company highlights a $3 billion U.S. market opportunity with ~472,500 annual procedures. Phase III trials target 80 patients, with enrollment completion expected in Q3 2026 and PMA submission starting late 2027. Phase II data showed significant improvements over microfracture. Regentis secured $6.5 million in June 2026 and plans European commercialization starting in 2026.
- Regentis outlined GelrinC, an acellular PEG hydrogel implant positioned as an off-the-shelf option for knee cartilage repair. * U.S. opportunity framed at about 472,500 cartilage-damage procedures annually, implying an estimated USD 3 billion addressable market. * Phase III pivotal IDE trial targets 80 patients; enrollment completion expected in Q3 2026; PMA submission work expected to start end-2027. * Phase II data cited KOOS and VAS improvements about 100% greater than microfracture at 24 months; mean MOCART 88.8 at 24 months. * Financing update cited USD 6.5 million gross proceeds in June 2026; European commercialization efforts starting 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here